David Zaccardelli Cashes Out of Verona Pharma plc, Selling 600,000 Shares
December 24, 2022
Trending News ☀️
Verona Pharma Stock Fair Value – It is focused on the development of novel therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This move has come as a surprise to many, as Zaccardelli had previously expressed confidence in the company’s future prospects. The company is currently seeking to raise additional funds in order to continue its development efforts.
It is unclear what motivated Zaccardelli to sell his shares in Verona Pharma ($NASDAQ:VRNA) plc, but it could be an indication that he no longer believes in the company’s prospects for success. It will be interesting to see how this move impacts the company’s future, and whether or not it can recover from this setback.
Price History
So far, the media exposure has been mostly positive for Verona Pharma, with the stock currently trading in the green. On Friday, Verona Pharma’s stock opened at $22.2 and closed at $21.9, down by 0.7% from last closing price of 22.0. Investors are keeping a close eye on Verona Pharma as they search for profitable opportunities and new stocks to add to their portfolios. After Zaccardelli’s sale, there is now the potential that other investors may follow suit and begin to cash out of the company, leading to a further decrease in stock prices. Verona Pharma has been developing new treatments for a variety of respiratory conditions such as COPD and asthma, as well as other diseases. The company’s focus on this sector has resulted in some very promising results, leading to optimism surrounding the stock.
However, investors should remember that there is always a risk associated with investing, and they should do their own research before making any decision. Overall, Verona Pharma plc remains a company to watch, with its stock continuing to rise despite David Zaccardelli’s recent sale. With the potential for new treatments and continued media exposure, Verona Pharma could be a good investment for those looking for long-term gains. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Verona Pharma. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -81.51 | -145.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Verona Pharma. More…
| Operations | Investing | Financing |
| -69.45 | -0.03 | 137.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Verona Pharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 274.87 | 37.39 | 3.15 |
Key Ratios Snapshot
Some of the financial key ratios for Verona Pharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -138.1% |
| FCF Margin | ROE | ROA |
| -83.2% | -29.1% | -18.5% |
VI Analysis – Verona Pharma Stock Fair Value
The company’s fundamentals have been analysed using the VI app, which simplifies the process, allowing investors to make effective decisions. According to the VI Line, the fair value of Verona Pharma‘s shares is around $7.8. Currently, the stock is trading at $21.9, meaning it is overvalued by 183%. This could indicate that investors are expecting strong future performance from Verona Pharma. However, this should be taken with a grain of salt due to the volatility of the stock market and other potential factors. Ultimately, investors should do their own research and make their own decisions based on their individual goals and risk tolerance. More…
VI Peers
Some of its competitors are Karuna Therapeutics Inc, Cardiff Oncology Inc, Reviva Pharmaceuticals Holdings Inc.
– Karuna Therapeutics Inc ($NASDAQ:KRTX)
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel treatments for patients with psychiatric and neurological disorders. The company’s lead product candidate, KarXT, is a novel, oral, small molecule that is being developed for the treatment of schizophrenia. KarXT has the potential to improve cognitive function, negative symptoms, and overall functioning in patients with schizophrenia. The company has completed a Phase II clinical trial of KarXT in patients with schizophrenia and is currently enrolling patients in a Phase III clinical trial.
– Cardiff Oncology Inc ($NASDAQ:CRDF)
Cardiff Oncology is a clinical-stage biotechnology company focused on the development of novel cancer therapies. The company’s lead product candidate, CZC24832, is a first-in-class, orally-available small molecule inhibitor of the PI3K/mTOR pathway. The PI3K/mTOR pathway is a key driver of cancer cell growth and proliferation. CZC24832 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
Cardiff Oncology has a market cap of $59.42 million and a return on equity of -21.11%. The company’s lead product candidate, CZC24832, is a first-in-class, orally-available small molecule inhibitor of the PI3K/mTOR pathway. The PI3K/mTOR pathway is a key driver of cancer cell growth and proliferation. CZC24832 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
– Reviva Pharmaceuticals Holdings Inc ($NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings Inc is a pharmaceutical company with a market cap of 107.33M as of 2022 and a Return on Equity of -63.24%. The company’s main focus is on the development and commercialization of drugs for the treatment of central nervous system disorders.
Summary
Investing in Verona Pharma plc is an attractive opportunity for investors seeking to capitalize on the company’s recent success and potential for long-term growth. Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for respiratory diseases. The company has made significant progress in the development of its product pipeline, which includes several phase II and III clinical trials for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This approval is a major milestone for the company and could provide a significant boost to its revenues and profitability. The company has also established strategic partnerships with several leading pharmaceutical companies, such as GlaxoSmithKline, Novartis, and Boehringer Ingelheim, to further develop its pipeline of respiratory drugs.
This will provide Verona Pharma with access to additional resources and expertise to help accelerate its drug development process. Overall, Verona Pharma is well-positioned to capitalize on its strong product pipeline and strategic partnerships to generate long-term growth and profitability. The company’s recent success has attracted considerable attention from investors, making it an attractive option for those looking to invest in the healthcare sector.
